APAF-CRT Mortality Trial

Jason Gencher presented the APAF-CRT Mortality Trial which was an international, open-label, blinded outcome trial of patients with severely symptomatic permanent atrial fibrillation for greater than 6 months, a narrow QRS (≤110 ms) and at least one HF hospitalization in the previous year. The patients were randomized to either ablation plus CRT or to pharmacological rate control. Patients were followed for a median of 29 months looking at a primary endpoint of all-cause mortality. The trial was published in the European Heart Journal in December and presented at ESC this past summer.